ClinicalTrials.gg
CompletedNCT03548337Updated Sep 30, 2020Results posted

Study To Describe The Safety, Tolerability, And Immunogenicity Of 13- Valent Pneumococcal Conjugate Vaccine Formulated In Multidose Vials When Given With Routine Pediatric Vaccines In Healthy Infants In India

A Phase 4 interventional study of 13vPnC in Vaccines, sponsored by Pfizer. Completed at 7 sites in India. Open to participants aged 42 Days to 72 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-09-30.

Sponsored by Pfizer · Phase 4, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
301
Allocation
Randomized
Ages
42 Days to 72 Days
Sex
All
01

Study summary

A Phase 4 Study To Describe The Safety, Tolerability, And Immunogenicity Of 13- Valent Pneumococcal Conjugate Vaccine Formulated In Multidose Vials When Given With Routine Pediatric Vaccines In Healthy Infants In India

Read the detailed description

A Phase 4, Randomized, Open-label Trial To Describe The Safety, Tolerability, And Immunogenicity Of 13- Valent Pneumococcal Conjugate Vaccine Formulated In Multidose Vials When Given With Routine Pediatric Vaccines In Healthy Infants In India

02

Conditions studied

  • Vaccines
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
42 Days to 72 Days
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Evidence of a personally signed and dated document indicating that the parent(s)/legal guardian(s) has/have been informed of all pertinent aspects of the study.
  2. Parent(s)/legal guardian(s)/caregiver(s) willing and able to comply with scheduled visits, treatment plan, and other study procedures.
  3. Aged 6 weeks (42 to 72 days) at the time of vaccination. (The day of birth is considered Day 0.)
  4. Available for the entire study period and whose parent(s)/legal guardian(s)/caregiver(s) can be reached by telephone.
  5. Healthy infant as determined by medical history, physical examination, and judgment of the investigator.
  6. Weight of 3.0 kg or greater at the time of vaccination.

Exclusion criteria

Exclusion Criteria:

  1. Infant who is a direct descendant (child, grandchild) of

    • Investigator site staff members directly involved in the conduct of the study, or
    • Site staff members otherwise supervised by the investigator, or
    • Pfizer employees directly involved in the conduct of the study.
  2. Participation in other studies involving drug(s) within 28 days prior to study entry and/or during study participation. Participation in purely observational studies is acceptable.
  3. Previous vaccination with licensed or investigational pneumococcal conjugate vaccine.
  4. A previous anaphylactic reaction to any vaccine or vaccine-related component.
  5. to vaccination with pneumococcal conjugate vaccine, or any other vaccine or vaccine component. Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
  6. Known or suspected immune deficiency or suppression, including known infection.
  7. Major known congenital malformation or serious chronic disorder.
  8. Significant neurological disorder or history of seizure including febrile seizure, or significant stable or evolving disorders such as cerebral palsy, encephalopathy, hydrocephalus, or other significant disorders. Does not include resolving syndromes due to birth trauma such as Erb's palsy.
  9. Other acute or chronic medical condition including recent laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
  10. Receipt of blood products or gamma globulin (including immunoglobulin and monoclonal antibodies, eg, Synagis).
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
301 participants (actual)

Study arms

  • Active comparator
    13vPnC with 2-PE from a MDV

    Multi Dose Vial with preservative

    Biological: 13vPnC

  • Active comparator
    13vPnC without 2-PE in a PFS

    Pre Filled Syringe without preservative

    Biological: 13vPnC

Interventions

  • Biological13vPnC

    13vPnC MultiDose Vial with preservative compared to a Prefilled syringe containing 13vPnC without any preservative

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Local Reactions Within 7 Days After Vaccination 1

    Local reactions were recorded daily using an electronic diary. Local reactions included redness, swelling and pain at injection site. Redness and swelling were graded as mild (0.5 to 2.5 centimeters \[cm\]), moderate (2.5 to 7.0 cm) and, severe (greater than \[\>\] 7 cm). Pain at injection site was graded as mild (hurt if gently touched (example, whimpers, winces, protests, or withdraws), moderate (hurt if gently touched \[with crying\]), and severe (caused limitation of limb movement). Participants may be represented in more than 1 row. Here, "Any" for redness, swelling and pain at injection site represents any grade of these local reactions among mild, moderate or severe.

    Time frame: Within 7 days after Vaccination 1

  2. Percentage of Participants With Systemic Events Within 7 Days After Vaccination 1

    Systemic events included fever, decreased appetite, drowsiness(increased sleep) and irritability,were recorded daily using an electronic diary. Fever graded as:1)less than (\<)38.0 degrees Celsius \[C\], 2)greater than or equal to(\>=)38.0 degree C to 38.4 degree C, 3)38.5 degree C to 38.9 degree C, 4) 39.0 degree C to 40.0 degree C, 5) \>40.0 degree C. Decreased appetite graded as: mild(decreased interest in eating), moderate(decreased oral intake), and severe(refusal to feed). Drowsiness graded as:mild(increased or prolonged sleeping bouts), moderate(slightly subdued; interfering with daily activity), and severe(disabling; not interested in usual daily activity). Irritability graded as: mild(easily consolable), moderate(required increased attention), and severe(inconsolable; crying could not be comforted). Participants may be represented in \>1 row. Here,"Any" for decreased appetite, drowsiness, irritability represents any grade of these systemic reactions among mild, moderate or severe.

    Time frame: Within 7 days after Vaccination 1

  3. Percentage of Participants With Local Reactions Within 7 Days After Vaccination 2

    Local reactions were recorded daily using an electronic diary. Local reactions included redness, swelling and pain at injection site. Redness and swelling were graded as mild (0.5 to 2.5 cm), moderate (2.5 to 7.0 cm) and, severe (\> 7 cm). Pain at injection site was graded as mild (hurt if gently touched (example, whimpers, winces, protests, or withdraws), moderate (hurt if gently touched \[with crying\]), and severe (caused limitation of limb movement). Participants may be represented in more than 1 row. Here, "Any" for redness, swelling and pain at injection site represents any grade of these local reactions among mild, moderate or severe.

    Time frame: Within 7 days after Vaccination 2

  4. Percentage of Participants With Systemic Events Within 7 Days After Vaccination 2

    Systemic events included fever, decreased appetite, drowsiness(increased sleep) and irritability, were recorded daily using an electronic diary. Fever graded as:1) \< 38.0 degrees C, 2) \>= 38.0 degree C to 38.4 degree C, 3)38.5 degree C to 38.9 degree C, 4) 39.0 degree C to 40.0 degree C, 5) \>40.0 degree C. Decreased appetite graded as: mild(decreased interest in eating), moderate(decreased oral intake), and severe(refusal to feed). Drowsiness graded as: mild (increased or prolonged sleeping bouts), moderate (slightly subdued; interfering with daily activity), and severe (disabling; not interested in usual daily activity). Irritability graded as: mild (easily consolable), moderate (required increased attention), and severe (inconsolable; crying could not be comforted). Participants may be represented in \>1 row. Here, "Any" for decreased appetite, drowsiness, irritability represents any grade of these systemic reactions among mild, moderate or severe.

    Time frame: Within 7 days after Vaccination 2

  5. Percentage of Participants With Local Reactions Within 7 Days After Vaccination 3

    Local reactions were recorded daily using an electronic diary. Local reactions included redness, swelling and pain at injection site. Redness and swelling were graded as mild (0.5 to 2.5 cm), moderate (2.5 to 7.0 cm) and, severe (\> 7 cm). Pain at injection site was graded as mild (hurt if gently touched (example, whimpers, winces, protests, or withdraws), moderate (hurt if gently touched \[with crying\]), and severe (caused limitation of limb movement). Participants may be represented in more than 1 row. Here, "Any" for redness, swelling and pain at injection site represents any grade of these local reactions among mild, moderate or severe.

    Time frame: Within 7 days after Vaccination 3

  6. Percentage of Participants With Systemic Events Within 7 Days After Vaccination 3

    Systemic events included fever, decreased appetite, drowsiness(increased sleep) and irritability, were recorded daily using an electronic diary. Fever graded as:1) \< 38.0 degrees C, 2) \>= 38.0 degree C to 38.4 degree C, 3)38.5 degree C to 38.9 degree C, 4) 39.0 degree C to 40.0 degree C, 5) \>40.0 degree C. Decreased appetite graded as: mild(decreased interest in eating), moderate(decreased oral intake), and severe(refusal to feed). Drowsiness graded as: mild (increased or prolonged sleeping bouts), moderate (slightly subdued; interfering with daily activity), and severe (disabling; not interested in usual daily activity). Irritability graded as: mild (easily consolable), moderate (required increased attention), and severe (inconsolable; crying could not be comforted). Participants may be represented in \>1 row. Here, "Any" for decreased appetite, drowsiness, irritability represents any grade of these systemic reactions among mild, moderate or severe.

    Time frame: Within 7 days after Vaccination 3

  7. Percentage of Participants With Local Reactions Within 7 Days After Vaccination 4

    Local reactions were recorded daily using an electronic diary. Local reactions included redness, swelling and pain at injection site. Redness and swelling were graded as mild (0.5 to 2.5 cm), moderate (2.5 to 7.0 cm) and, severe (\> 7 cm). Pain at injection site was graded as mild (hurt if gently touched (example, whimpers, winces, protests, or withdraws), moderate (hurt if gently touched \[with crying\]), and severe (caused limitation of limb movement). Participants may be represented in more than 1 row. Here, "Any" for redness, swelling and pain at injection site represents any grade of these local reactions among mild, moderate or severe.

    Time frame: Within 7 days after Vaccination 4

  8. Percentage of Participants With Systemic Events Within 7 Days After Vaccination 4

    Systemic events included fever, decreased appetite, drowsiness(increased sleep) and irritability, were recorded daily using an electronic diary. Fever graded as:1) \< 38.0 degrees C, 2) \>= 38.0 degree C to 38.4 degree C, 3)38.5 degree C to 38.9 degree C, 4) 39.0 degree C to 40.0 degree C, 5) \>40.0 degree C. Decreased appetite graded as: mild(decreased interest in eating), moderate(decreased oral intake), and severe(refusal to feed). Drowsiness graded as: mild (increased or prolonged sleeping bouts), moderate (slightly subdued; interfering with daily activity), and severe (disabling; not interested in usual daily activity). Irritability graded as: mild (easily consolable), moderate (required increased attention), and severe (inconsolable; crying could not be comforted). Participants may be represented in \>1 row. Here, "Any" for decreased appetite, drowsiness, irritability represents any grade of these systemic reactions among mild, moderate or severe.

    Time frame: Within 7 days after Vaccination 4

  9. Percentage of Participants With Adverse Events (AEs) After Vaccination 1 up to 1 Month After Vaccination 3

    An AE was any untoward medical occurrence in a participant who received study vaccine without regard to possibility of causal relationship.

    Time frame: From Vaccination 1 up to 1 Month after Vaccination 3 (for a maximum study duration of 3 months)

  10. Percentage of Participants With Adverse Events (AEs) From Vaccination 4 up to 1 Month After Vaccination 4

    An AE was any untoward medical occurrence in a participant who received study vaccine without regard to possibility of causal relationship.

    Time frame: From Vaccination 4 up to 1 month after Vaccination 4 (for a maximum study duration of 1 month)

  11. Percentage of Participants With Serious Adverse Events (SAEs) After Vaccination 1 up to 1 Month After Vaccination 4

    An AE was any untoward medical occurrence in a participant who received study vaccine without regard to possibility of causal relationship. A SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

    Time frame: From Vaccination 1 up to 1 month after Vaccination 4 (for a maximum study duration of 11.5 months)

  12. Number of Participants With New Diagnosed Chronic Medical Condition (NDCMC) From 1 Month After Vaccination 3 up to Vaccination 4

    A newly diagnosed chronic medical condition was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.

    Time frame: From 1 month after Vaccination 3 up to Vaccination 4 (for a maximum study duration of 7.5 months)

Secondary outcomes

  1. Percentage of Participants With Immunoglobulin G (IgG) Concentrations Greater Than or Equal to (>=) Pre-defined Thresholds for Each of the Pneumococcal Serotypes Measured 1 Month After Vaccination 3

    Percentage of participants achieving predefined antibody threshold: \>=0.35 microgram per milliliter (mcg/mL) for the 10 pneumococcal serotypes 1, 3, 4, 6A, 7F, 9V, 14, 18C, 19F and 23F; threshold \>= 0.23 mcg/mL for serotype 5, threshold \>= 0.10 mcg/mL for serotype 6B, threshold \>= 0.12 mcg/mL for serotype 19A, along with the corresponding 95 percent (%) confidence interval (CI) are reported.

    Time frame: 1 month after Vaccination 3

  2. Percentage of Participants With Immunoglobulin G (IgG) Concentrations Greater Than or Equal to (>=) Pre-defined Thresholds for Each of the Pneumococcal Serotypes Measured 1 Month After Vaccination 4

    Percentage of participants achieving predefined antibody threshold \>=0.35 mcg/mL for the 10 pneumococcal serotypes 1, 3, 4, 6A, 7F, 9V, 14, 18C, 19F and 23F, threshold \>= 0.23 mcg/mL for serotype 5, threshold \>= 0.10 mcg/mL for serotype 6B, threshold \>= 0.12 mcg/mL for serotype 19A, along with the corresponding 95% CI are reported.

    Time frame: 1 month after Vaccination 4

  3. Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for Each of Pneumococcal Serotypes Measured 1 Month After Vaccination 3

    Antibody (IgG) GMCs for the 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) and corresponding 2-sided 95% CI are reported.

    Time frame: 1 month after Vaccination 3

  4. Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for Each of Pneumococcal Serotypes Measured 1 Month After Vaccination 4

    Antibody (IgG) GMCs for the 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) and corresponding 2-sided 95% CI are reported.

    Time frame: 1 month after Vaccination 4

  5. Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for Each of Pneumococcal Serotypes Measured 1 Month After Vaccination 3

    Antibody-mediated serum OPA against the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) was measured centrally using a pneumococcal OPA assay. Initial results were measured as OPA titers, which were then logarithmically transformed for analysis; geometric means calculated and expressed as GMTs.

    Time frame: 1 month after Vaccination 3

  6. Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMT) for Each of Pneumococcal Serotypes Measured 1 Month After Vaccination 4

    Antibody-mediated serum OPA against the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) was measured centrally using a pneumococcal OPA assay. Initial results were measured as OPA titers, which were then logarithmically transformed for analysis; geometric means calculated and expressed as GMTs.

    Time frame: 1 month after Vaccination 4

  7. Percentage of Participants With Opsonophagocytic Activity (OPA) Titers >= Lower Limit of Quantitation (LLOQ) for Each of Pneumococcal Serotypes Measured 1 Month After Vaccination 3

    Percentage of participants achieving OPA titer \>=LLOQ along with 95% CI for the 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) determined in blood samples of participants was presented. LLOQ (measured in mcg/mL) for each serotype is as follows: Serotype 1=18; Serotype 3=12; Serotype 4=21; Serotype 5=29; Serotype 6A=37; Serotype 6B=43; Serotype 7F=113; Serotype 9V=141; Serotype 14=35; Serotype 18C=31; Serotype 19A=18; Serotype 19F=48; Serotype 23F=13.

    Time frame: 1 month after Vaccination 3

  8. Percentage of Participants With Opsonophagocytic Activity (OPA) Titers >= Lower Limit of Quantitation (LLOQ) for Each of Pneumococcal Serotypes Measured 1 Month After Vaccination 4

    Percentage of participants achieving OPA titer \>=LLOQ along with 95% CI for the 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) determined in blood samples of participants was presented. LLOQ (measured in mcg/mL) for each serotype is as follows: Serotype 1=18; Serotype 3=12; Serotype 4=21; Serotype 5=29; Serotype 6A=37; Serotype 6B=43; Serotype 7F=113; Serotype 9V=141; Serotype 14=35; Serotype 18C=31; Serotype 19A=18; Serotype 19F=48; Serotype 23F=13.

    Time frame: 1 month after Vaccination 4

07

Results

Posted Sep 30, 2020

Participant flow

Infant Series
Participant flow — Infant Series
Milestone13vPnC: Multi-dose Vial (With Preservative)13vPnC: Single-dose Prefilled Syringe (Without Preservative)
Started151150
Vaccination 1150150
Vaccination 2144144
Vaccination 3144141
Completed139139
Not completed1211
Withdrew: Withdrawal by parent/guardian88
Withdrew: No longer met eligibility criteria10
Withdrew: Lost to follow-up21
Withdrew: Adverse event02
Withdrew: Randomized but not vaccinated10
Toddler Dose
Participant flow — Toddler Dose
Milestone13vPnC: Multi-dose Vial (With Preservative)13vPnC: Single-dose Prefilled Syringe (Without Preservative)
Started139139
Vaccination 4139139
Completed138138
Not completed11
Withdrew: Withdrawal by parent/guardian11

Outcome measures

PrimaryPercentage of Participants With Local Reactions Within 7 Days After Vaccination 1

Local reactions were recorded daily using an electronic diary. Local reactions included redness, swelling and pain at injection site. Redness and swelling were graded as mild (0.5 to 2.5 centimeters \[cm\]), moderate (2.5 to 7.0 cm) and, severe (greater than \[\>\] 7 cm). Pain at injection site was graded as mild (hurt if gently touched (example, whimpers, winces, protests, or withdraws), moderate (hurt if gently touched \[with crying\]), and severe (caused limitation of limb movement). Participants may be represented in more than 1 row. Here, "Any" for redness, swelling and pain at injection site represents any grade of these local reactions among mild, moderate or severe.

Time frame:
Within 7 days after Vaccination 1
Reported as:
Number · percentage of participants
Percentage of Participants With Local Reactions Within 7 Days After Vaccination 1
percentage of participants13vPnC: Multi-dose Vial (With Preservative)13vPnC: Single-dose Prefilled Syringe (Without Preservative)
Redness: Any19.7 (13.6 to 27.1)16.9 (11.2 to 23.9)
Redness: Mild17.7 (11.9 to 24.8)12.8 (7.9 to 19.3)
Redness: Moderate2.0 (0.4 to 5.8)4.1 (1.5 to 8.6)
Redness: Severe0 (0.0 to 2.5)0 (0.0 to 2.5)
Swelling: Any27.9 (20.8 to 35.9)33.8 (26.2 to 42.0)
Swelling: Mild21.8 (15.4 to 29.3)23.6 (17.1 to 31.3)
Swelling: Moderate6.1 (2.8 to 11.3)10.1 (5.8 to 16.2)
Swelling: Severe0 (0.0 to 2.5)0 (0.0 to 2.5)
Pain at injection site: Any61.9 (53.5 to 69.8)67.6 (59.4 to 75.0)
Pain at injection site: Mild28.6 (21.4 to 36.6)33.1 (25.6 to 41.3)
Pain at injection site: Moderate30.6 (23.3 to 38.7)29.1 (21.9 to 37.1)
Pain at injection site: Severe2.7 (0.7 to 6.8)5.4 (2.4 to 10.4)
PrimaryPercentage of Participants With Systemic Events Within 7 Days After Vaccination 1

Systemic events included fever, decreased appetite, drowsiness(increased sleep) and irritability,were recorded daily using an electronic diary. Fever graded as:1)less than (\<)38.0 degrees Celsius \[C\], 2)greater than or equal to(\>=)38.0 degree C to 38.4 degree C, 3)38.5 degree C to 38.9 degree C, 4) 39.0 degree C to 40.0 degree C, 5) \>40.0 degree C. Decreased appetite graded as: mild(decreased interest in eating), moderate(decreased oral intake), and severe(refusal to feed). Drowsiness graded as:mild(increased or prolonged sleeping bouts), moderate(slightly subdued; interfering with daily activity), and severe(disabling; not interested in usual daily activity). Irritability graded as: mild(easily consolable), moderate(required increased attention), and severe(inconsolable; crying could not be comforted). Participants may be represented in \>1 row. Here,"Any" for decreased appetite, drowsiness, irritability represents any grade of these systemic reactions among mild, moderate or severe.

Time frame:
Within 7 days after Vaccination 1
Reported as:
Number · percentage of participants
Percentage of Participants With Systemic Events Within 7 Days After Vaccination 1
percentage of participants13vPnC: Multi-dose Vial (With Preservative)13vPnC: Single-dose Prefilled Syringe (Without Preservative)
Fever: <38.0 degree C15.0 (9.6 to 21.8)10.8 (6.3 to 17.0)
Fever: >=38.0 degree C to 38.4 degree C10.9 (6.4 to 17.1)8.1 (4.3 to 13.7)
Fever: 38.5 degree C to 38.9 degree C1.4 (0.2 to 4.8)2.7 (0.7 to 6.8)
Fever: 39.0 degree C to 40.0 degree C1.4 (0.2 to 4.8)0 (0.0 to 2.5)
Fever: >40.0 degree C1.4 (0.2 to 4.8)0 (0.0 to 2.5)
Decreased appetite: Any42.2 (34.1 to 50.6)53.4 (45.0 to 61.6)
Decreased appetite: Mild23.8 (17.2 to 31.5)30.4 (23.1 to 38.5)
Decreased appetite: Moderate17.7 (11.9 to 24.8)21.6 (15.3 to 29.1)
Decreased appetite: Severe0.7 (0.0 to 3.7)1.4 (0.2 to 4.8)
Drowsiness: Any55.1 (46.7 to 63.3)66.2 (58.0 to 73.8)
Drowsiness: Mild29.3 (22.0 to 37.3)33.1 (25.6 to 41.3)
Drowsiness: Moderate25.2 (18.4 to 33.0)31.1 (23.7 to 39.2)
Drowsiness: Severe0.7 (0.0 to 3.7)2.0 (0.4 to 5.8)
Irritability: Any64.6 (56.3 to 72.3)65.5 (57.3 to 73.2)
Irritability: Mild37.4 (29.6 to 45.8)32.4 (25.0 to 40.6)
Irritability: Moderate21.8 (15.4 to 29.3)26.4 (19.5 to 34.2)
Irritability: Severe5.4 (2.4 to 10.4)6.8 (3.3 to 12.1)
PrimaryPercentage of Participants With Local Reactions Within 7 Days After Vaccination 2

Local reactions were recorded daily using an electronic diary. Local reactions included redness, swelling and pain at injection site. Redness and swelling were graded as mild (0.5 to 2.5 cm), moderate (2.5 to 7.0 cm) and, severe (\> 7 cm). Pain at injection site was graded as mild (hurt if gently touched (example, whimpers, winces, protests, or withdraws), moderate (hurt if gently touched \[with crying\]), and severe (caused limitation of limb movement). Participants may be represented in more than 1 row. Here, "Any" for redness, swelling and pain at injection site represents any grade of these local reactions among mild, moderate or severe.

Time frame:
Within 7 days after Vaccination 2
Reported as:
Number · percentage of participants
Percentage of Participants With Local Reactions Within 7 Days After Vaccination 2
percentage of participants13vPnC: Multi-dose Vial (With Preservative)13vPnC: Single-dose Prefilled Syringe (Without Preservative)
Redness: Any17.0 (11.2 to 24.3)19.3 (13.1 to 26.8)
Redness: Mild16.3 (10.6 to 23.5)17.9 (11.9 to 25.2)
Redness: Moderate0.7 (0.0 to 3.9)1.4 (0.2 to 5.1)
Redness: Severe0 (0.0 to 2.6)0 (0.0 to 2.6)
Swelling: Any24.8 (17.9 to 32.8)27.9 (20.6 to 36.1)
Swelling: Mild21.3 (14.8 to 29.0)22.9 (16.2 to 30.7)
Swelling: Moderate3.5 (1.2 to 8.1)5.0 (2.0 to 10.0)
Swelling: Severe0 (0.0 to 2.6)0 (0.0 to 2.6)
Pain at injection site: Any59.6 (51.0 to 67.7)62.1 (53.6 to 70.2)
Pain at injection site: Mild32.6 (25.0 to 41.0)29.3 (21.9 to 37.6)
Pain at injection site: Moderate20.6 (14.2 to 28.2)26.4 (19.3 to 34.5)
Pain at injection site: Severe6.4 (3.0 to 11.8)6.4 (3.0 to 11.9)
PrimaryPercentage of Participants With Systemic Events Within 7 Days After Vaccination 2

Systemic events included fever, decreased appetite, drowsiness(increased sleep) and irritability, were recorded daily using an electronic diary. Fever graded as:1) \< 38.0 degrees C, 2) \>= 38.0 degree C to 38.4 degree C, 3)38.5 degree C to 38.9 degree C, 4) 39.0 degree C to 40.0 degree C, 5) \>40.0 degree C. Decreased appetite graded as: mild(decreased interest in eating), moderate(decreased oral intake), and severe(refusal to feed). Drowsiness graded as: mild (increased or prolonged sleeping bouts), moderate (slightly subdued; interfering with daily activity), and severe (disabling; not interested in usual daily activity). Irritability graded as: mild (easily consolable), moderate (required increased attention), and severe (inconsolable; crying could not be comforted). Participants may be represented in \>1 row. Here, "Any" for decreased appetite, drowsiness, irritability represents any grade of these systemic reactions among mild, moderate or severe.

Time frame:
Within 7 days after Vaccination 2
Reported as:
Number · percentage of participants
Percentage of Participants With Systemic Events Within 7 Days After Vaccination 2
percentage of participants13vPnC: Multi-dose Vial (With Preservative)13vPnC: Single-dose Prefilled Syringe (Without Preservative)
Fever: <38.0 degree C8.5 (4.5 to 14.4)8.6 (4.5 to 14.5)
Fever: >=38.0 degree C to 38.4 degree C6.4 (3.0 to 11.8)5.7 (2.5 to 10.9)
Fever: 38.5 degree C to 38.9 degree C2.1 (0.4 to 6.1)2.1 (0.4 to 6.1)
Fever: 39.0 degree C to 40.0 degree C0 (0.0 to 2.6)0 (0.0 to 2.6)
Fever: >40.0 degree C0 (0.0 to 2.6)0.7 (0.0 to 3.9)
Decreased appetite: Any40.4 (32.3 to 49.0)38.6 (30.5 to 47.2)
Decreased appetite: Mild27.0 (19.8 to 35.1)25.0 (18.1 to 33.0)
Decreased appetite: Moderate12.1 (7.2 to 18.6)12.1 (7.2 to 18.7)
Decreased appetite: Severe1.4 (0.2 to 5.0)1.4 (0.2 to 5.1)
Drowsiness: Any50.4 (41.8 to 58.9)52.1 (43.5 to 60.7)
Drowsiness: Mild23.4 (16.7 to 31.3)22.1 (15.6 to 29.9)
Drowsiness: Moderate25.5 (18.6 to 33.6)26.4 (19.3 to 34.5)
Drowsiness: Severe1.4 (0.2 to 5.0)3.6 (1.2 to 8.1)
Irritability: Any56.7 (48.1 to 65.0)60.0 (51.4 to 68.2)
Irritability: Mild29.1 (21.7 to 37.3)37.9 (29.8 to 46.4)
Irritability: Moderate24.8 (17.9 to 32.8)17.9 (11.9 to 25.2)
Irritability: Severe2.8 (0.8 to 7.1)4.3 (1.6 to 9.1)
PrimaryPercentage of Participants With Local Reactions Within 7 Days After Vaccination 3

Local reactions were recorded daily using an electronic diary. Local reactions included redness, swelling and pain at injection site. Redness and swelling were graded as mild (0.5 to 2.5 cm), moderate (2.5 to 7.0 cm) and, severe (\> 7 cm). Pain at injection site was graded as mild (hurt if gently touched (example, whimpers, winces, protests, or withdraws), moderate (hurt if gently touched \[with crying\]), and severe (caused limitation of limb movement). Participants may be represented in more than 1 row. Here, "Any" for redness, swelling and pain at injection site represents any grade of these local reactions among mild, moderate or severe.

Time frame:
Within 7 days after Vaccination 3
Reported as:
Number · percentage of participants
Percentage of Participants With Local Reactions Within 7 Days After Vaccination 3
percentage of participants13vPnC: Multi-dose Vial (With Preservative)13vPnC: Single-dose Prefilled Syringe (Without Preservative)
Redness: Any20.1 (13.8 to 27.8)22.9 (16.2 to 30.7)
Redness: Mild20.1 (13.8 to 27.8)20.0 (13.7 to 27.6)
Redness: Moderate0 (0.0 to 2.6)2.9 (0.8 to 7.2)
Redness: Severe0 (0.0 to 2.6)0 (0.0 to 2.6)
Swelling: Any23.0 (16.3 to 30.9)27.1 (20.0 to 35.3)
Swelling: Mild20.9 (14.4 to 28.6)23.6 (16.8 to 31.5)
Swelling: Moderate2.2 (0.4 to 6.2)2.9 (0.8 to 7.2)
Swelling: Severe0 (0.0 to 2.6)0.7 (0.0 to 3.9)
Pain at injection site: Any55.4 (46.7 to 63.8)54.3 (45.7 to 62.7)
Pain at injection site: Mild30.2 (22.7 to 38.6)27.9 (20.6 to 36.1)
Pain at injection site: Moderate23.0 (16.3 to 30.9)21.4 (14.9 to 29.2)
Pain at injection site: Severe2.2 (0.4 to 6.2)5.0 (2.0 to 10.0)
PrimaryPercentage of Participants With Systemic Events Within 7 Days After Vaccination 3

Systemic events included fever, decreased appetite, drowsiness(increased sleep) and irritability, were recorded daily using an electronic diary. Fever graded as:1) \< 38.0 degrees C, 2) \>= 38.0 degree C to 38.4 degree C, 3)38.5 degree C to 38.9 degree C, 4) 39.0 degree C to 40.0 degree C, 5) \>40.0 degree C. Decreased appetite graded as: mild(decreased interest in eating), moderate(decreased oral intake), and severe(refusal to feed). Drowsiness graded as: mild (increased or prolonged sleeping bouts), moderate (slightly subdued; interfering with daily activity), and severe (disabling; not interested in usual daily activity). Irritability graded as: mild (easily consolable), moderate (required increased attention), and severe (inconsolable; crying could not be comforted). Participants may be represented in \>1 row. Here, "Any" for decreased appetite, drowsiness, irritability represents any grade of these systemic reactions among mild, moderate or severe.

Time frame:
Within 7 days after Vaccination 3
Reported as:
Number · percentage of participants
Percentage of Participants With Systemic Events Within 7 Days After Vaccination 3
percentage of participants13vPnC: Multi-dose Vial (With Preservative)13vPnC: Single-dose Prefilled Syringe (Without Preservative)
Fever: <38.0 degree C7.2 (3.5 to 12.8)9.3 (5.0 to 15.4)
Fever: >=38.0 degree C to 38.4 degree C4.3 (1.6 to 9.2)6.4 (3.0 to 11.9)
Fever: 38.5 degree C to 38.9 degree C2.2 (0.4 to 6.2)1.4 (0.2 to 5.1)
Fever: 39.0 degree C to 40.0 degree C0 (0.0 to 2.6)1.4 (0.2 to 5.1)
Fever: >40.0 degree C0.7 (0.0 to 3.9)0 (0.0 to 2.6)
Decreased appetite: Any34.5 (26.7 to 43.1)36.4 (28.5 to 45.0)
Decreased appetite: Mild20.1 (13.8 to 27.8)23.6 (16.8 to 31.5)
Decreased appetite: Moderate11.5 (6.7 to 18.0)10.0 (5.6 to 16.2)
Decreased appetite: Severe2.9 (0.8 to 7.2)2.9 (0.8 to 7.2)
Drowsiness: Any36.0 (28.0 to 44.5)39.3 (31.1 to 47.9)
Drowsiness: Mild20.9 (14.4 to 28.6)19.3 (13.1 to 26.8)
Drowsiness: Moderate13.7 (8.4 to 20.5)17.9 (11.9 to 25.2)
Drowsiness: Severe1.4 (0.2 to 5.1)2.1 (0.4 to 6.1)
Irritability: Any54.7 (46.0 to 63.1)60.0 (51.4 to 68.2)
Irritability: Mild31.7 (24.0 to 40.1)37.9 (29.8 to 46.4)
Irritability: Moderate19.4 (13.2 to 27.0)15.7 (10.1 to 22.8)
Irritability: Severe3.6 (1.2 to 8.2)6.4 (3.0 to 11.9)
PrimaryPercentage of Participants With Local Reactions Within 7 Days After Vaccination 4

Local reactions were recorded daily using an electronic diary. Local reactions included redness, swelling and pain at injection site. Redness and swelling were graded as mild (0.5 to 2.5 cm), moderate (2.5 to 7.0 cm) and, severe (\> 7 cm). Pain at injection site was graded as mild (hurt if gently touched (example, whimpers, winces, protests, or withdraws), moderate (hurt if gently touched \[with crying\]), and severe (caused limitation of limb movement). Participants may be represented in more than 1 row. Here, "Any" for redness, swelling and pain at injection site represents any grade of these local reactions among mild, moderate or severe.

Time frame:
Within 7 days after Vaccination 4
Reported as:
Number · percentage of participants
Percentage of Participants With Local Reactions Within 7 Days After Vaccination 4
percentage of participants13vPnC: Multi-dose Vial (With Preservative)13vPnC: Single-dose Prefilled Syringe (Without Preservative)
Redness: Any8.3 (4.2 to 14.4)11.4 (6.5 to 18.0)
Redness: MIld8.3 (4.2 to 14.4)10.6 (5.9 to 17.2)
Redness: Moderate0 (0.0 to 2.8)0.8 (0.0 to 4.1)
Redness: Severe0 (0.0 to 2.8)0 (0.0 to 2.8)
Swelling: Any9.1 (4.8 to 15.3)12.1 (7.1 to 18.9)
Swelling: Mild6.8 (3.2 to 12.5)11.4 (6.5 to 18.0)
Swelling: Moderate2.3 (0.5 to 6.5)0.8 (0.0 to 4.1)
Swelling: Severe0 (0.0 to 2.8)0 (0.0 to 2.8)
Pain at injection site: Any25.0 (17.9 to 33.3)19.7 (13.3 to 27.5)
Pain at injection site: Mild18.9 (12.6 to 26.7)13.6 (8.3 to 20.7)
Pain at injection site: Moderate6.1 (2.7 to 11.6)5.3 (2.2 to 10.6)
Pain at injection site: Severe0 (0.0 to 2.8)0.8 (0.0 to 4.1)
PrimaryPercentage of Participants With Systemic Events Within 7 Days After Vaccination 4

Systemic events included fever, decreased appetite, drowsiness(increased sleep) and irritability, were recorded daily using an electronic diary. Fever graded as:1) \< 38.0 degrees C, 2) \>= 38.0 degree C to 38.4 degree C, 3)38.5 degree C to 38.9 degree C, 4) 39.0 degree C to 40.0 degree C, 5) \>40.0 degree C. Decreased appetite graded as: mild(decreased interest in eating), moderate(decreased oral intake), and severe(refusal to feed). Drowsiness graded as: mild (increased or prolonged sleeping bouts), moderate (slightly subdued; interfering with daily activity), and severe (disabling; not interested in usual daily activity). Irritability graded as: mild (easily consolable), moderate (required increased attention), and severe (inconsolable; crying could not be comforted). Participants may be represented in \>1 row. Here, "Any" for decreased appetite, drowsiness, irritability represents any grade of these systemic reactions among mild, moderate or severe.

Time frame:
Within 7 days after Vaccination 4
Reported as:
Number · percentage of participants
Percentage of Participants With Systemic Events Within 7 Days After Vaccination 4
percentage of participants13vPnC: Multi-dose Vial (With Preservative)13vPnC: Single-dose Prefilled Syringe (Without Preservative)
Fever: <38.0 degree C3.0 (0.8 to 7.6)4.5 (1.7 to 9.6)
Fever: >=38.0 degree C to 38.4 degree C1.5 (0.2 to 5.4)3.8 (1.2 to 8.6)
Fever: 38.5 degree C to 38.9 degree C0 (0.0 to 2.8)0 (0.0 to 2.8)
Fever: 39.0 degree C to 40.0 degree C0 (0.0 to 2.8)0.8 (0.0 to 4.1)
Fever: >40.0 degree C1.5 (0.2 to 5.4)0 (0.0 to 2.8)
Decreased appetite: Any15.2 (9.5 to 22.4)16.7 (10.7 to 24.1)
Decreased appetite: Mild10.6 (5.9 to 17.2)6.8 (3.2 to 12.5)
Decreased appetite: Moderate4.5 (1.7 to 9.6)9.8 (5.3 to 16.3)
Decreased appetite: Severe0 (0.0 to 2.8)0 (0.0 to 2.8)
Drowsiness: Any7.6 (3.7 to 13.5)18.9 (12.6 to 26.7)
Drowsiness: Mild3.8 (1.2 to 8.6)12.9 (7.7 to 19.8)
Drowsiness: Moderate3.8 (1.2 to 8.6)6.1 (2.7 to 11.6)
Drowsiness: Severe0 (0.0 to 2.8)0 (0.0 to 2.8)
Irritability: Any24.2 (17.2 to 32.5)23.5 (16.5 to 31.6)
Irritability: Mild15.9 (10.1 to 23.3)16.7 (10.7 to 24.1)
Irritability: Moderate7.6 (3.7 to 13.5)5.3 (2.2 to 10.6)
Irritability: Severe0.8 (0.0 to 4.1)1.5 (0.2 to 5.4)
PrimaryPercentage of Participants With Adverse Events (AEs) After Vaccination 1 up to 1 Month After Vaccination 3

An AE was any untoward medical occurrence in a participant who received study vaccine without regard to possibility of causal relationship.

Time frame:
From Vaccination 1 up to 1 Month after Vaccination 3 (for a maximum study duration of 3 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Adverse Events (AEs) After Vaccination 1 up to 1 Month After Vaccination 3
percentage of participants13vPnC: Multi-dose Vial (With Preservative)13vPnC: Single-dose Prefilled Syringe (Without Preservative)
Percentage of Participants With Adverse Events (AEs) After Vaccination 1 up to 1 Month After Vaccination 347.3 (39.1 to 55.6)49.3 (41.1 to 57.6)
PrimaryPercentage of Participants With Adverse Events (AEs) From Vaccination 4 up to 1 Month After Vaccination 4

An AE was any untoward medical occurrence in a participant who received study vaccine without regard to possibility of causal relationship.

Time frame:
From Vaccination 4 up to 1 month after Vaccination 4 (for a maximum study duration of 1 month)
Reported as:
Number · percentage of participants
Percentage of Participants With Adverse Events (AEs) From Vaccination 4 up to 1 Month After Vaccination 4
percentage of participants13vPnC: Multi-dose Vial (With Preservative)13vPnC: Single-dose Prefilled Syringe (Without Preservative)
Percentage of Participants With Adverse Events (AEs) From Vaccination 4 up to 1 Month After Vaccination 47.9 (4.0 to 13.7)8.6 (4.5 to 14.6)
PrimaryPercentage of Participants With Serious Adverse Events (SAEs) After Vaccination 1 up to 1 Month After Vaccination 4

An AE was any untoward medical occurrence in a participant who received study vaccine without regard to possibility of causal relationship. A SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

Time frame:
From Vaccination 1 up to 1 month after Vaccination 4 (for a maximum study duration of 11.5 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Serious Adverse Events (SAEs) After Vaccination 1 up to 1 Month After Vaccination 4
percentage of participants13vPnC: Multi-dose Vial (With Preservative)13vPnC: Single-dose Prefilled Syringe (Without Preservative)
Percentage of Participants With Serious Adverse Events (SAEs) After Vaccination 1 up to 1 Month After Vaccination 48.0 (4.2 to 13.6)4.7 (1.9 to 9.4)
PrimaryNumber of Participants With New Diagnosed Chronic Medical Condition (NDCMC) From 1 Month After Vaccination 3 up to Vaccination 4

A newly diagnosed chronic medical condition was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.

Time frame:
From 1 month after Vaccination 3 up to Vaccination 4 (for a maximum study duration of 7.5 months)
Reported as:
Count of participants · Participants
Number of Participants With New Diagnosed Chronic Medical Condition (NDCMC) From 1 Month After Vaccination 3 up to Vaccination 4
Participants13vPnC: Multi-dose Vial (With Preservative)13vPnC: Single-dose Prefilled Syringe (Without Preservative)
Number of Participants With New Diagnosed Chronic Medical Condition (NDCMC) From 1 Month After Vaccination 3 up to Vaccination 400
SecondaryPercentage of Participants With Immunoglobulin G (IgG) Concentrations Greater Than or Equal to (>=) Pre-defined Thresholds for Each of the Pneumococcal Serotypes Measured 1 Month After Vaccination 3

Percentage of participants achieving predefined antibody threshold: \>=0.35 microgram per milliliter (mcg/mL) for the 10 pneumococcal serotypes 1, 3, 4, 6A, 7F, 9V, 14, 18C, 19F and 23F; threshold \>= 0.23 mcg/mL for serotype 5, threshold \>= 0.10 mcg/mL for serotype 6B, threshold \>= 0.12 mcg/mL for serotype 19A, along with the corresponding 95 percent (%) confidence interval (CI) are reported.

Time frame:
1 month after Vaccination 3
Reported as:
Number · percentage of participants
Percentage of Participants With Immunoglobulin G (IgG) Concentrations Greater Than or Equal to (>=) Pre-defined Thresholds for Each of the Pneumococcal Serotypes Measured 1 Month After Vaccination 3
percentage of participants13vPnC: Multi-dose Vial (With Preservative)13vPnC: Single-dose Prefilled Syringe (Without Preservative)
Serotype: 191.2 (85.1 to 95.4)85.0 (77.7 to 90.6)
Serotype: 391.9 (86.0 to 95.9)85.7 (78.6 to 91.2)
Serotype: 491.2 (85.1 to 95.4)91.0 (84.8 to 95.3)
Serotype: 584.6 (77.4 to 90.2)82.0 (74.4 to 88.1)
Serotype: 6A83.8 (76.5 to 89.6)71.4 (63.0 to 78.9)
Serotype: 6B77.2 (69.2 to 84.0)75.2 (67.0 to 82.3)
Serotype: 7F96.3 (91.6 to 98.8)93.2 (87.5 to 96.9)
Serotype: 9V85.3 (78.2 to 90.8)83.5 (76.0 to 89.3)
Serotype: 1488.2 (81.6 to 93.1)82.7 (75.2 to 88.7)
Serotype: 18C92.6 (86.9 to 96.4)84.2 (76.9 to 90.0)
Serotype: 19A100.0 (97.3 to 100.0)98.5 (94.7 to 99.8)
Serotype: 19F97.8 (93.7 to 99.5)95.5 (90.4 to 98.3)
Serotype: 23F84.6 (77.4 to 90.2)76.7 (68.6 to 83.6)
SecondaryPercentage of Participants With Immunoglobulin G (IgG) Concentrations Greater Than or Equal to (>=) Pre-defined Thresholds for Each of the Pneumococcal Serotypes Measured 1 Month After Vaccination 4

Percentage of participants achieving predefined antibody threshold \>=0.35 mcg/mL for the 10 pneumococcal serotypes 1, 3, 4, 6A, 7F, 9V, 14, 18C, 19F and 23F, threshold \>= 0.23 mcg/mL for serotype 5, threshold \>= 0.10 mcg/mL for serotype 6B, threshold \>= 0.12 mcg/mL for serotype 19A, along with the corresponding 95% CI are reported.

Time frame:
1 month after Vaccination 4
Reported as:
Number · percentage of participants
Percentage of Participants With Immunoglobulin G (IgG) Concentrations Greater Than or Equal to (>=) Pre-defined Thresholds for Each of the Pneumococcal Serotypes Measured 1 Month After Vaccination 4
percentage of participants13vPnC: Multi-dose Vial (With Preservative)13vPnC: Single-dose Prefilled Syringe (Without Preservative)
Serotype: 199.2 (95.9 to 100.0)100.0 (97.2 to 100.0)
Serotype: 397.0 (92.4 to 99.2)98.4 (94.5 to 99.8)
Serotype: 499.2 (95.9 to 100.0)100.0 (97.2 to 100.0)
Serotype: 599.2 (95.9 to 100.0)100.0 (97.2 to 100.0)
Serotype: 6A96.2 (91.4 to 98.8)96.9 (92.3 to 99.1)
Serotype: 6B98.5 (94.6 to 99.8)96.9 (92.3 to 99.1)
Serotype: 7F99.2 (95.9 to 100.0)99.2 (95.8 to 100.0)
Serotype: 9V98.5 (94.6 to 99.8)99.2 (95.8 to 100.0)
Serotype: 1497.7 (93.5 to 99.5)96.1 (91.2 to 98.7)
Serotype: 18C97.0 (92.4 to 99.2)99.2 (95.8 to 100.0)
Serotype: 19A99.2 (95.9 to 100.0)99.2 (95.8 to 100.0)
Serotype: 19F98.5 (94.6 to 99.8)100.0 (97.2 to 100.0)
Serotype: 23F99.2 (95.9 to 100.0)96.9 (92.3 to 99.1)
SecondaryImmunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for Each of Pneumococcal Serotypes Measured 1 Month After Vaccination 3

Antibody (IgG) GMCs for the 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) and corresponding 2-sided 95% CI are reported.

Time frame:
1 month after Vaccination 3
Reported as:
Geometric mean · mcg/mL
Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for Each of Pneumococcal Serotypes Measured 1 Month After Vaccination 3
mcg/mL13vPnC: Multi-dose Vial (With Preservative)13vPnC: Single-dose Prefilled Syringe (Without Preservative)
Serotype: 11.36 (1.15 to 1.60)1.13 (0.94 to 1.36)
Serotype: 31.01 (0.88 to 1.16)0.93 (0.80 to 1.07)
Serotype: 41.67 (1.40 to 1.98)1.75 (1.45 to 2.11)
Serotype: 50.83 (0.67 to 1.02)0.86 (0.67 to 1.11)
Serotype: 6A1.45 (1.13 to 1.87)0.86 (0.66 to 1.12)
Serotype: 6B0.41 (0.31 to 0.55)0.33 (0.24 to 0.46)
Serotype: 7F2.01 (1.74 to 2.33)1.85 (1.52 to 2.26)
Serotype: 9V1.42 (1.17 to 1.73)1.28 (1.02 to 1.62)
Serotype: 141.66 (1.33 to 2.06)1.39 (1.09 to 1.76)
Serotype: 18C1.81 (1.50 to 2.18)1.37 (1.10 to 1.71)
Serotype: 19A2.33 (1.96 to 2.78)1.86 (1.51 to 2.28)
Serotype: 19F2.89 (2.52 to 3.31)2.43 (2.04 to 2.89)
Serotype: 23F1.48 (1.20 to 1.81)0.94 (0.73 to 1.21)
SecondaryImmunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for Each of Pneumococcal Serotypes Measured 1 Month After Vaccination 4

Antibody (IgG) GMCs for the 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) and corresponding 2-sided 95% CI are reported.

Time frame:
1 month after Vaccination 4
Reported as:
Geometric mean · mcg/mL
Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for Each of Pneumococcal Serotypes Measured 1 Month After Vaccination 4
mcg/mL13vPnC: Multi-dose Vial (With Preservative)13vPnC: Single-dose Prefilled Syringe (Without Preservative)
Serotype: 14.35 (3.71 to 5.10)4.27 (3.65 to 4.99)
Serotype: 31.58 (1.36 to 1.83)1.63 (1.43 to 1.86)
Serotype: 410.58 (8.89 to 12.60)11.91 (10.19 to 13.93)
Serotype: 55.16 (4.37 to 6.10)5.68 (4.81 to 6.70)
Serotype: 6A18.55 (14.32 to 24.02)20.51 (16.32 to 25.78)
Serotype: 6B11.76 (9.24 to 14.98)10.87 (8.14 to 14.53)
Serotype: 7F7.92 (6.88 to 9.13)8.29 (7.17 to 9.57)
Serotype: 9V8.78 (7.19 to 10.73)9.57 (8.00 to 11.44)
Serotype: 1413.20 (10.69 to 16.30)11.78 (9.31 to 14.90)
Serotype: 18C6.21 (5.19 to 7.44)6.27 (5.25 to 7.48)
Serotype: 19A12.26 (10.26 to 14.65)12.02 (9.75 to 14.82)
Serotype: 19F13.65 (11.16 to 16.69)14.09 (11.71 to 16.96)
Serotype: 23F10.89 (8.78 to 13.50)9.90 (7.75 to 12.66)
SecondaryOpsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for Each of Pneumococcal Serotypes Measured 1 Month After Vaccination 3

Antibody-mediated serum OPA against the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) was measured centrally using a pneumococcal OPA assay. Initial results were measured as OPA titers, which were then logarithmically transformed for analysis; geometric means calculated and expressed as GMTs.

Time frame:
1 month after Vaccination 3
Reported as:
Geometric mean · titer (1/dilution)
Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for Each of Pneumococcal Serotypes Measured 1 Month After Vaccination 3
titer (1/dilution)13vPnC: Multi-dose Vial (With Preservative)13vPnC: Single-dose Prefilled Syringe (Without Preservative)
Serotype: 121.8 (18.1 to 26.2)22.5 (18.1 to 27.9)
Serotype: 379.7 (68.8 to 92.3)72.8 (62.7 to 84.6)
Serotype: 41158.8 (938.3 to 1431.1)1159.2 (948.3 to 1417.0)
Serotype: 537.0 (31.4 to 43.5)40.9 (34.0 to 49.3)
Serotype: 6A1211.7 (896.4 to 1638.0)1321.9 (1026.7 to 1701.9)
Serotype: 6B1145.8 (870.4 to 1508.3)957.6 (708.2 to 1294.8)
Serotype: 7F1743.3 (1436.6 to 2115.5)1178.8 (952.6 to 1458.6)
Serotype: 9V643.9 (498.6 to 831.7)683.3 (522.6 to 893.3)
Serotype: 14496.9 (344.2 to 717.3)341.8 (236.0 to 495.0)
Serotype: 18C3055.8 (2378.5 to 3926.0)2183.9 (1686.9 to 2827.3)
Serotype: 19A219.3 (169.4 to 283.9)275.7 (212.0 to 358.6)
Serotype: 19F236.1 (191.6 to 291.1)272.7 (219.1 to 339.4)
Serotype: 23F1036.4 (746.9 to 1438.0)926.8 (673.9 to 1274.7)
SecondaryOpsonophagocytic Activity (OPA) Geometric Mean Titers (GMT) for Each of Pneumococcal Serotypes Measured 1 Month After Vaccination 4

Antibody-mediated serum OPA against the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) was measured centrally using a pneumococcal OPA assay. Initial results were measured as OPA titers, which were then logarithmically transformed for analysis; geometric means calculated and expressed as GMTs.

Time frame:
1 month after Vaccination 4
Reported as:
Geometric mean · titer (1/dilution)
Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMT) for Each of Pneumococcal Serotypes Measured 1 Month After Vaccination 4
titer (1/dilution)13vPnC: Multi-dose Vial (With Preservative)13vPnC: Single-dose Prefilled Syringe (Without Preservative)
Serotype: 1204.2 (164.7 to 253.3)217.0 (176.4 to 266.9)
Serotype: 3121.0 (104.4 to 140.3)129.8 (111.7 to 150.8)
Serotype: 42991.4 (2437.5 to 3671.3)2519.0 (2098.7 to 3023.6)
Serotype: 5157.6 (131.9 to 188.3)153.4 (126.6 to 185.8)
Serotype: 6A2945.7 (2376.0 to 3652.1)3092.5 (2493.5 to 3835.4)
Serotype: 6B1948.9 (1521.4 to 2496.7)1750.1 (1360.9 to 2250.8)
Serotype: 7F4161.5 (3498.0 to 4950.9)4353.8 (3706.5 to 5114.0)
Serotype: 9V6927.5 (5765.9 to 8323.2)6460.4 (5277.3 to 7908.7)
Serotype: 141505.8 (1246.5 to 1819.0)1302.2 (1106.1 to 1533.2)
Serotype: 18C8028.3 (6233.7 to 10339.7)7830.0 (5998.5 to 10220.7)
Serotype: 19A1848.9 (1472.0 to 2322.2)1832.5 (1454.9 to 2308.1)
Serotype: 19F808.0 (633.0 to 1033.5)766.0 (609.2 to 963.2)
Serotype: 23F3125.0 (2450.8 to 3984.7)3348.8 (2639.5 to 4248.5)
SecondaryPercentage of Participants With Opsonophagocytic Activity (OPA) Titers >= Lower Limit of Quantitation (LLOQ) for Each of Pneumococcal Serotypes Measured 1 Month After Vaccination 3

Percentage of participants achieving OPA titer \>=LLOQ along with 95% CI for the 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) determined in blood samples of participants was presented. LLOQ (measured in mcg/mL) for each serotype is as follows: Serotype 1=18; Serotype 3=12; Serotype 4=21; Serotype 5=29; Serotype 6A=37; Serotype 6B=43; Serotype 7F=113; Serotype 9V=141; Serotype 14=35; Serotype 18C=31; Serotype 19A=18; Serotype 19F=48; Serotype 23F=13.

Time frame:
1 month after Vaccination 3
Reported as:
Number · percentage of participants
Percentage of Participants With Opsonophagocytic Activity (OPA) Titers >= Lower Limit of Quantitation (LLOQ) for Each of Pneumococcal Serotypes Measured 1 Month After Vaccination 3
percentage of participants13vPnC: Multi-dose Vial (With Preservative)13vPnC: Single-dose Prefilled Syringe (Without Preservative)
Serotype: 151.4 (41.7 to 61.0)46.2 (36.5 to 56.2)
Serotype: 398.2 (93.5 to 99.8)98.1 (93.4 to 99.8)
Serotype: 498.1 (93.3 to 99.8)99.0 (94.6 to 100.0)
Serotype: 562.3 (52.7 to 71.2)62.6 (52.7 to 71.8)
Serotype: 6A91.2 (84.3 to 95.7)94.4 (88.2 to 97.9)
Serotype: 6B94.5 (88.4 to 98.0)92.3 (85.4 to 96.6)
Serotype: 7F99.0 (94.3 to 100.0)96.8 (90.9 to 99.3)
Serotype: 9V88.3 (80.5 to 93.8)88.0 (80.0 to 93.6)
Serotype: 1482.9 (74.6 to 89.4)76.9 (67.8 to 84.4)
Serotype: 18C98.1 (93.2 to 99.8)98.0 (92.9 to 99.8)
Serotype: 19A92.1 (85.0 to 96.5)95.7 (89.2 to 98.8)
Serotype: 19F89.7 (82.3 to 94.8)91.4 (84.4 to 96.0)
Serotype: 23F94.9 (88.6 to 98.3)94.9 (88.5 to 98.3)
SecondaryPercentage of Participants With Opsonophagocytic Activity (OPA) Titers >= Lower Limit of Quantitation (LLOQ) for Each of Pneumococcal Serotypes Measured 1 Month After Vaccination 4

Percentage of participants achieving OPA titer \>=LLOQ along with 95% CI for the 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) determined in blood samples of participants was presented. LLOQ (measured in mcg/mL) for each serotype is as follows: Serotype 1=18; Serotype 3=12; Serotype 4=21; Serotype 5=29; Serotype 6A=37; Serotype 6B=43; Serotype 7F=113; Serotype 9V=141; Serotype 14=35; Serotype 18C=31; Serotype 19A=18; Serotype 19F=48; Serotype 23F=13.

Time frame:
1 month after Vaccination 4
Reported as:
Number · percentage of participants
Percentage of Participants With Opsonophagocytic Activity (OPA) Titers >= Lower Limit of Quantitation (LLOQ) for Each of Pneumococcal Serotypes Measured 1 Month After Vaccination 4
percentage of participants13vPnC: Multi-dose Vial (With Preservative)13vPnC: Single-dose Prefilled Syringe (Without Preservative)
Serotype: 197.1 (91.9 to 99.4)97.1 (91.6 to 99.4)
Serotype: 398.1 (93.4 to 99.8)100.0 (96.4 to 100.0)
Serotype: 4100.0 (96.4 to 100.0)100.0 (96.3 to 100.0)
Serotype: 595.2 (89.2 to 98.4)97.1 (91.6 to 99.4)
Serotype: 6A100.0 (96.5 to 100.0)99.0 (94.6 to 100.0)
Serotype: 6B97.0 (91.6 to 99.4)95.0 (88.8 to 98.4)
Serotype: 7F100.0 (96.3 to 100.0)100.0 (96.0 to 100.0)
Serotype: 9V100.0 (96.4 to 100.0)99.0 (94.4 to 100.0)
Serotype: 14100.0 (96.6 to 100.0)100.0 (96.4 to 100.0)
Serotype: 18C99.0 (94.6 to 100.0)99.0 (94.6 to 100.0)
Serotype: 19A100.0 (96.3 to 100.0)99.0 (94.3 to 100.0)
Serotype: 19F96.1 (90.3 to 98.9)97.0 (91.4 to 99.4)
Serotype: 23F99.0 (94.7 to 100.0)99.0 (94.3 to 100.0)

Adverse events

Collected over Infant series: SAEs and non-SAEs= from Vaccination 1 up to 1 month post Vaccination 3 (for 3 months). Between infant series and toddler dose: SAEs:1 month post Vaccination 3 up to pre-vaccination 4 (for 7.5 months), non-SAEs were not planned to be collected. Toddler dose: SAEs and non-SAEs = up to 1 month post Vaccination 4 (for 1 month). Local reactions and systemic events =7 days post any vaccination (systematic assessment). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
13vPnC, MDV With Preservative: Infant Series0/150 (0%)5/150 (3.3%)145/150 (96.7%)
13vPnC, PFS Without Preservative: Infant Series0/150 (0%)4/150 (2.7%)141/150 (94%)
13vPnC, MDV: Between Infant Series and Toddler Dose0/150 (0%)6/150 (4%)—
13vPnC, PFS: Between Infant Series and Toddler Dose0/150 (0%)3/150 (2%)—
13vPnC, MDV With Preservative: Toddler Dose0/139 (0%)1/139 (0.7%)58/139 (41.7%)
13vPnC, PFS Without Preservative: Toddler Dose0/139 (0%)0/139 (0%)54/139 (38.8%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
Event13vPnC, MDV With Preservative: Infant Series13vPnC, PFS Without Preservative: Infant Series13vPnC, MDV: Between Infant Series and Toddler Dose13vPnC, PFS: Between Infant Series and Toddler Dose13vPnC, MDV With Preservative: Toddler Dose13vPnC, PFS Without Preservative: Toddler Dose
BronchiolitisInfections and infestations4/1502/1500/1500/1500/1390/139
SeizureNervous system disorders0/1502/1501/1500/1500/1390/139
Escherichia urinary tract infectionInfections and infestations0/1500/1500/1500/1501/1390/139
Febrile convulsionNervous system disorders0/1500/1501/1500/1501/1390/139
AnaemiaBlood and lymphatic system disorders0/1501/1500/1500/1500/1390/139
Lower respiratory tract infectionInfections and infestations1/1500/1501/1501/1500/1390/139
Urinary tract infectionInfections and infestations0/1501/1501/1500/1500/1390/139
Lower respiratory tract infection viralInfections and infestations0/1500/1501/1500/1500/1390/139
Viral infectionInfections and infestations0/1500/1501/1500/1500/1390/139
CellulitisInfections and infestations0/1500/1500/1501/1500/1390/139
Most frequent other events
Showing 10 of 11
Most frequent other events
Event13vPnC, MDV With Preservative: Infant Series13vPnC, PFS Without Preservative: Infant Series13vPnC, MDV: Between Infant Series and Toddler Dose13vPnC, PFS: Between Infant Series and Toddler Dose13vPnC, MDV With Preservative: Toddler Dose13vPnC, PFS Without Preservative: Toddler Dose
Injection site pain-2General disorders117/150125/150——33/13926/139
IrritabilityPsychiatric disorders114/150117/150——32/13931/139
Hypersomnia (Increased sleep)Nervous system disorders105/150116/150——10/13925/139
Decreased appetiteMetabolism and nutrition disorders92/150107/150——20/13922/139
SwellingGeneral disorders64/15070/150——12/13916/139
Erythema (Redness)Skin and subcutaneous tissue disorders52/15049/150——11/13915/139
Injection site pain-1General disorders44/15046/150——0/1390/139
Pyrexia-2General disorders37/15032/150——0/1390/139
Injection site swellingGeneral disorders17/15016/150——0/1390/139
Upper respiratory tract infectionInfections and infestations16/15010/150——0/1390/139

Baseline characteristics

Safety population included all participants who received at least 1 dose of study vaccine.

Age, Continuous
Age, Continuous(Weeks)13vPnC: Multi-dose Vial (With Preservative)13vPnC: Single-dose Prefilled Syringe (Without Preservative)Total
Mean6.9 ± 0.956.9 ± 0.996.9 ± 0.97
Sex: Female, Male
Sex: Female, Male(Participants)13vPnC: Multi-dose Vial (With Preservative)13vPnC: Single-dose Prefilled Syringe (Without Preservative)Total
Female7467141
Male7683159
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)13vPnC: Multi-dose Vial (With Preservative)13vPnC: Single-dose Prefilled Syringe (Without Preservative)Total
Hispanic or Latino000
Not Hispanic or Latino150150300
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)13vPnC: Multi-dose Vial (With Preservative)13vPnC: Single-dose Prefilled Syringe (Without Preservative)Total
American Indian or Alaska Native000
Asian150150300
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
08

Study locations

7 sites
  • B. J. Medical College & Civil Hospital
    Ahmedabad, Gujarat 380016, India
  • Manipal Hospital
    Bengaluru, Karnataka 560017, India
  • KEM Hospital Research Centre
    Pune, Maharashtra 411 011, India
  • Bharati Vidyapeeth University Medical College
    Pune, Maharashtra 411043, India
  • Sri Ramachandra Hospital
    Chennai, Tamil NADU 600116, India
  • Kanchi Kamakoti Childs Trust Hospital
    Chennai, Tamil Nadu, 600034, India
  • Sir Ganga Ram Hospital
    New Delhi, 110060, India
09

References and documents

Publications

  • Lalwani SK, Ramanan PV, Sapru A, Sundaram B, Shah BH, Kaul D, Karthik Nagesh N, Kalina WV, Chand R, Ding M, Suroju S, Scott DA, Lockhart SP. Safety and immunogenicity of a multidose vial formulation of 13-valent pneumococcal conjugate vaccine administered with routine pediatric vaccines in healthy infants in India: A phase 4, randomized, open-label study. Vaccine. 2021 Nov 5;39(46):6787-6795. doi: 10.1016/j.vaccine.2021.09.029. Epub 2021 Oct 14. PubMed 34656378 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2018 to primary completion in Dec 2019, 18 months.

Results were first posted in Sep 2020, 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2018
First posted
Jun 7, 2018
StartActual
May 31, 2018
Primary completionActual
Dec 20, 2019
CompletionActual
Dec 20, 2019
Results first posted
Sep 30, 2020
Last update
Sep 30, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 30, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03548337
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jun 7, 2018
Start date
May 31, 2018
Primary completion
Dec 20, 2019
Completion
Dec 20, 2019
Results posted
Sep 30, 2020
Last update
Sep 30, 2020

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 13-valent pneumococcal vaccine

Start the discussion